← Leaderboards
Richard B Freeman
Tufts Medical Center
$623,948
Attributed
$623,948
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $163K · FY2005–10$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$623,948 · 6
By mechanism
R21$538,470 · 2
M01$85,478 · 4
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Marshall Kaplan$85,478
- Young Mee Lee$93,073
- Shirley Tsunoda$85,478
- L. K. George Hsu$609,252
- Karim Fawaz$42,739
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationLiver TransplantationDrug Screening /EvaluationTransplantationPharmacokineticsCyclosporinesDrug Adverse EffectDosageImmunosuppressiveImmunosuppressionControl GroupsAlgorithmsConsciousConflict (Psychology)BaseAccountingCohortAnniversaryAffectEffective TherapyEventDiagnosis
Grant awards (12)
Long Term Outcome for Liver Transplantation for Hepatocellular Carcinoma$137,460
R21 · FY2010 · CA · contact PI
Long Term Outcome for Liver Transplantation for Hepatocellular Carcinoma$75,260
R21 · FY2009 · CA · contact PI
Liver Transplantation for Hepatocellular Carcinoma$163,000
R21 · FY2005 · DK
Liver Transplantation for Hepatocellular Carcinoma$162,750
R21 · FY2004 · DK
Neoral as primary immunosuppressant therapy in transplant patients$0
M01 · FY2002 · RR
Safety, tolerability &pharmacokinetics of SDZ RAD in de novo liver transplant$0
M01 · FY2002 · RR
Neoral as primary immunosuppressant therapy in transplant patients$0
M01 · FY2001 · RR
Safety, tolerability &pharmacokinetics of SDZ RAD in de novo liver transplant$0
M01 · FY2001 · RR
COMPARE INTRA/INTER PATIENT VARIABILITY OF CYCLOSPORIN PHARMACOKINETICS$42,739
M01 · FY2000 · RR
PHARMACOKINETICS OF GANCICLOVIR FOLLOWING ORAL VALGANCICLOVIR$42,739
M01 · FY2000 · RR
Safety, tolerability &pharmacokinetics of SDZ RAD in de novo liver transplant$0
M01 · FY2000 · RR
Neoral as primary immunosuppressant therapy in transplant patients$0
M01 · FY2000 · RR